Abstract 591P
Background
Survival rates of childhood cancer are continuously improving, and the overall survival rate is now over 80%. Gonadotoxicity and reduced fertility are well-known side effects of cancer treatment. With the increasing rates of survival, there is a growing population of childhood cancer survivors (CCS) who are reaching fertile age and may want to have children. The aim of this study is to present the baseline data from inclusion of a prospective follow-up study of fertility surveillance in children diagnosed with cancer. We are striving to evaluate if Anti-Mullerian Hormone (AMH) could be used as a surveillance modality in prospective monitoring of ovarian reserve in female CCS.
Methods
Participants were enrolled in the study between May 2016 and March 2021. Eighty-six girls between 0-17 years were included at the Paediatric Oncology Center at Sahlgrenska University Hospital in Gothenburg, Sweden. Inclusion criteria were new diagnosis of paediatric cancer and scheduled treatment with chemotherapy and/or radiotherapy. The cohort will be part of a longitudinal follow-up program until the patients are approximately 25 years old, having passed puberty and ovarian reserve in adult age can be evaluated. AMH levels are measured at inclusion and every 2 years. Fertility preservation treatment will be offered in appropriate cases.
Results
Mean age was 7.6 years (median 7.5). The most common type of cancer was solid tumours (n=34), followed by leukemia (n=23). In the cohort, 78 patients had initial AMH values and eight patients had not had an initial blood test assessed due to various reasons. The initial levels of AMH measured between 0.03 and 9.97 μg/L. The mean value was 1.8 μg/L and the median 1.2 μg/L. 55% of the participants had AMH values above 1.0 μg/L. Two patients were offered fertility preservation before initiation of cancer therapy.
Conclusions
This is a presentation of the baseline data from a cohort of girls diagnosed with cancer who are part of a long-term follow-up study. The long-term study has a unique prospective design that will follow girls from cancer diagnosis up to fertile age, assessing AMH levels and may identify who would be likely to benefit from fertility preservation, and when. The study will contribute to further knowledge of AMH and ovarian reserve in girls and adolescents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sahlgrenska University Hospital, the Hjalmar Svensson Foundation, and the Jane and Dan Olsson Research Foundation.
Disclosure
All authors have declared no conflicts of interest.